Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids
Status:
Completed
Trial end date:
2017-04-06
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the safety and efficacy of two vaginal
doses of Proellex® administered for up to 2 courses of treatment (18 weeks each), each
separated by an Off-Drug Interval (ODI), to premenopausal women with symptomatic uterine
fibroids.